Lower-dose combo vs. higher-dose alone for heart artery disease
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 or older.
- You have stable chest pain (angina) and tests show mild to moderate blockages (10% to 70%) in at least one heart artery.
- You have never had a stent or bypass surgery.
- You have never had a heart attack or stroke.
- You do not have severe kidney, liver, or lung disease, or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination pill of two cholesterol-lowering medicines (pitavastatin and ezetimibe) in adults who have been taking either atorvastatin or rosuvastatin for at least 3 months. It aims to see if switching to this new combination is safe and effective.
This study compares two ways to lower cholesterol and stabilize artery plaque in people with coronary artery disease who are having a stent procedure. It tests whether a moderate statin plus ezetimibe works as well as a high-intensity statin alone for stabilizing plaque.
This trial compares a combo of statin and ezetimibe without aspirin against statin alone with aspirin in people with high coronary calcium but no blocked arteries. It aims to find which approach is safer and more effective without causing bleeding risk.
This trial studies whether high-intensity statin plus ezetimibe can improve heart health in people who do not have symptoms but have calcium buildup in their heart arteries. It may help lower cholesterol and reduce future heart risks for the right participants.
This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.
This study compares two cholesterol treatment approaches after a heart attack: a lower dose combination versus a higher dose single medicine. It aims to see which option works well and is tolerable for people after a treated heart attack.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.